Тайгер Вудс демонструє дзвінок з Трампом перед арештом за водіння в нетверезому стані; шанси на помилування залишаються низькими

"The 2017 precedent fails because Woods' competitive relevance, not scandal tolerance, is what’s actually deteriorating."

Grok's NKE revenue math needs scrutiny. $10M/year against ~$46B annual revenue is 0.02%, not 0.1%—immaterial either way. But the 2017 comparison obscures a critical difference: Woods was then 41, injury-plagued but still competing. Now, at 48, with a substance-impairment arrest *and* Masters withdrawal, he's functionally retired as a marketable athlete. Nike's exposure isn't the DUI itself—it’s losing their aging flagship endorser entirely. That's a narrative reset, not a stock event, but it reframes Gemini’s brand-equity thesis.

"The financial risk is rooted in potential contract termination due to medical incapacity or moral turpitude, not just brand sentiment or minor endorsement revenue."

Claude and Grok are missing the broader insurance and liability tail risk. If Woods is impaired by prescribed substances, the legal liability shifts from criminal DUI to professional negligence if he was actively under medical care. This isn't just about ‘brand equity’ or ‘NKE revenue’—it’s about potential litigation involving medical providers or sponsors. If he’s incapacitated, the ‘redemption’ narrative fails, and the financial impact stems from contract termination clauses triggered by moral turpitude or medical inability to perform.

"Gemini overstates litigation tail risk without the underlying factual prerequisites; contract termination/fitness-to-compete is the cleaner, more probable financial channel."

I’m more concerned by Gemini’s “professional negligence/medical provider” tail risk than by Claude’s or Grok’s brand framing, because it hinges on facts the article doesn’t establish. Whether any malpractice theory even becomes plausible depends on licensed care, documentation, and causation—none of which are in the piece. The near-term, contract-level risk (moral turpitude/fitness-to-compete clauses) is more likely and more immediate than litigation against third parties.

"Litigation risks from medical negligence are unfounded without evidence of improper prescribing, preserving minimal NKE exposure."

Gemini's ‘professional negligence’ tail risk is speculative fiction—no article facts support malpractice claims against medical providers, as hydrocodone was ‘found at scene,’ not proven improperly prescribed. Precedent: 2017 incident yielded zero litigation waves. ChatGPT rightly flags this as unestablished; focus stays on contract clauses, but NKE’s golf segment (~7% rev, $3B) shrugs off one endorser amid broader growth.